Investor Presentation - US FDA 510(k) Clearance for Remplir
Filed with ASX · · 21 pages · English
In the deck
Story so far
Earlier from Orthocell
- First Sales of Striate in Germany, Austria & Swiss Region
- Regulatory approval to commence Striate sales in Singapore
- S&P DJI Announces March 2025 Quarterly Rebalance
- Orthocell Receives $3.18 million R&D Tax Refund
- Third Consecutive Quarter of Record Revenue for Orthocell
Later from Orthocell
- Regulatory Approval for Striate in US$65M Brazilian Market
- First US Distributors Signed for Remplirs US$1.6B market
- Remplir Approved to Commence Sales in US$84M Thai Market
- Pause in Trading
- Replacement Trading Halt
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell